ImmuCell (ICCC) Announces Earnings Results

ImmuCell (NASDAQ:ICCC) released its earnings results on Thursday. The biotechnology company reported ($0.04) earnings per share for the quarter, Bloomberg Earnings reports. ImmuCell had a return on equity of 0.28% and a net margin of 0.60%. The business had revenue of $3.13 million during the quarter.

ImmuCell (NASDAQ:ICCC) opened at $7.38 on Friday. The company has a market capitalization of $39.02, a price-to-earnings ratio of 738.00 and a beta of 1.03. ImmuCell has a 52 week low of $5.00 and a 52 week high of $9.25. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.99 and a current ratio of 1.75.

Separately, ValuEngine upgraded ImmuCell from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th.

COPYRIGHT VIOLATION NOTICE: “ImmuCell (ICCC) Announces Earnings Results” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.com-unik.info/2018/02/10/immucell-iccc-announces-earnings-results.html.

ImmuCell Company Profile

ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.

Earnings History for ImmuCell (NASDAQ:ICCC)

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit